

Resource Summary Report

Generated by [dkNET](#) on Aug 14, 2026

PharmKGB

RRID:SCR_025580

Type: Tool

Proper Citation

PharmKGB (RRID:SCR_025580)

Resource Information

URL: <https://www.pharmgkb.org/>

Proper Citation: PharmKGB (RRID:SCR_025580)

Description: NIH-funded resource that provides information about how human genetic variation affects response to medications. PharmGKB collects, curates and disseminates knowledge about clinically actionable gene-drug associations and genotype-phenotype relationships.

Synonyms: Pharmacogenomics Knowledgebase

Resource Type: data or information resource, knowledge base

Keywords: human genetic variation affects, response to medications, clinically actionable gene-drug associations, genotype-phenotype relationships,

Funding: NIH

Availability: Free, Freely available,

Resource Name: PharmKGB

Resource ID: SCR_025580

Record Creation Time: 20240806T053245+0000

Record Last Update: 20260808T190727+0000

Ratings and Alerts

No rating or validation information has been found for PharmKGB.

No alerts have been found for PharmKGB.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 318 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Yan H, et al. (2026) miR-376c-3p mediates icariin's anti-osteoclastogenic effect by targeting Mmp3. *Journal of orthopaedic surgery and research*, 21(1), 80.

Liu P, et al. (2026) Exploring the toxicological effects of Di-O-benzoyldiethylene glycol plasticizer on allergic rhinitis through network toxicology combined with molecular docking and molecular simulation. *Scientific reports*, 16(1).

He X, et al. (2026) Integration of bioinformatics analysis and experimental verification reveals the role of neutrophil extracellular traps in silica nanoparticles-induced lung injury. *Journal of nanobiotechnology*, 24(1).

Tang W, et al. (2026) Targeting cell membrane sphingolipids: a novel ceramide analog CeY-B1 inhibits migration and invasion in cervical cancer cells. *Journal of translational medicine*, 24(1).

Mu W, et al. (2026) Efficacy and potential pharmacological mechanisms of total glucosides of paeony in treating ankylosing spondylitis in Asian populations: a meta-analysis, network pharmacology, and molecular dynamics simulation. *Frontiers in nutrition*, 13, 1738150.

Wu L, et al. (2026) Exploring the mechanism of baicalein on choroid melanoma based on network pharmacology, transcriptomics and experimental verification. *Frontiers in pharmacology*, 17, 1787798.

Georgiou G, et al. (2026) Integrative Network Analysis of Single-Cell RNA Findings and a Priori Knowledge Highlights Gene Regulators in Multiple Myeloma Progression. *International journal of molecular sciences*, 27(2).

Chen C, et al. (2026) Computational-experimental study reveals direct target and bioactives of *Ajania fruticulosa* against NAFLD via TLR2/NF- κ B/PPAR- γ signaling. *NPJ science of food*, 10(1), 73.

Jaratlerdsiri W, et al. (2026) A catalogue of early diverged contemporary human genome variation reveals distinct Khoe-San populations. *Nature communications*, 17(1).

Xu A, et al. (2026) Fraxin Attenuates Rheumatoid Arthritis by Regulating Macrophage Polarization and Inhibiting Fibroblast-like Synoviocyte Proliferation. *International journal of molecular sciences*, 27(7).

He G, et al. (2026) Tu-Si-Zi-Wan reduces D-galactose-induced hepatic and cerebral oxidative damage in aging mice via the Nrf2/ARE pathway. *Metabolic brain disease*, 41(1).

Qu S, et al. (2026) Exploring the potential targets and mechanisms of malachite green induced lung adenocarcinoma through network toxicology and molecular docking. *Medicine*, 105(16), e48372.

Zhu X, et al. (2026) Sijing Pill modulates PGE2/EP4/PI3K-AKT pathway via gut-bone axis to treat postmenopausal osteoporosis. *Frontiers in microbiology*, 17, 1786197.

Akash SR, et al. (2026) GC-MS based tentative identification of β -sitosterol from *Brassica nigra* seeds and evaluation of its anticancer potential: An integrated in vitro and in silico study. *PloS one*, 21(6), e0351850.

Liu S, et al. (2026) Exploring the mechanism of action of Kaixin San in treating dementia based on network pharmacology and molecular docking. *Medicine*, 105(1), e46583.

Zhang Y, et al. (2026) Uncovering the mechanisms of Jingui Shenqi pill alleviates type 2 diabetic osteoporosis using a combined network pharmacology and metabolomics approach. *Scientific reports*, 16(1), 4890.

Yue Y, et al. (2026) Sijunzi decoction ameliorates geriatric sarcopenia by improving muscle strength, quality, and functions. *Medicine*, 105(14), e47154.

Ha X, et al. (2026) Pharmacogenomics-Guided Precision Therapy for Chronic Kidney Disease with Resistant Hypertension: A Prospective Cohort Study. *Kidney & blood pressure research*, 51(1), 36.

Ren Q, et al. (2026) Network pharmacology, molecular docking, and in vivo experiments reveal the effects of Polygonati Rhizoma on periodontitis. *Scientific reports*, 16(1).

Zhang Z, et al. (2026) Optimized New Shengmai Powder suppresses ferroptosis in ischemic cardiomyocytes via cGMP-PKG signalling. *Chinese medicine*, 21(1).